Report copyright - NSCLC overview - OverGroupEGFR-TKIs I line treatment of EGFR mutated NSCLC patients STUDIO TERAPIA PZ 0RR (%) PFS (m)IPASS Gefitinib vs CBDCA+Tax 261 71.2 vs 47.3 9.8 vs 6.4 First-Signal
Please pass captcha verification before submit form